Drug discovery in cardiovascular disease identified by text mining and data analysis

Zheng Wan†, Bin Zhao‡, Xiaohong Zhang, Yilin Zhao

Department of Oncology and Vascular Interventional Radiology, Zhongshan Hospital, Xiamen University, Xiamen, China

Contribution: (I) conception and design: Z Wan, B Zhao; (II) administrative support: Y Zhao; (III) provision of study materials or patients: B Zhao; (IV) collection and assembly of data: Z Wan, B Zhao; (V) data analysis and interpretation: Z Wan, B Zhao; (VI) manuscript writing: all authors; (VII) final approval of manuscript: all authors.

Background: Cardiovascular diseases are currently prevalent in cardiology and vascular surgery in the hospital. The purpose of this study based on text mining and microarray data analysis was designed to find some existing drugs target to gene and expand the potential new drug indications.

Methods: Firstly, we used text mining (“Atherosclerosis”) and microarray data analysis (GSE28829) to obtain a common set of genes. Secondly, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis performed to these genes, as well as protein-protein interaction (PPI) network. Then, the significant genes clustered in the PPI network were chose to execute gene-drug interaction analysis for potential drug discovery.

Results: We got 1,788 text mining genes (TMGs) and 275 differentially expressed genes (DEGs) through text mining and data analysis, respectively. Ninety-three genes were duplicated between TMGs and DEGs, in which 89 genes were up-regulated genes and four genes were down regulated. Twenty-three genes clustered in the significant gene module. Lastly, the eight out of 23 genes can target 20 existing drugs.

Conclusions: The findings of these eight genes (VCAM1, CSF1R, C5AR1, CXCR4, CD86, CCR1, ITGB2, TLR8), which were associated with inflammatory response, target to 20 existing drugs may expand drug indications to atherosclerosis-related disease.

Keywords: Text mining; differentially expressed genes (DEGs); genetic diagnosis; drug discovery


doi: 10.21037/apm-20-705

View this article at: http://dx.doi.org/10.21037/apm-20-705

Introduction

According to the World Health Organization (WHO) health report, atherosclerotic cardiovascular disease (ASCVD) is one of the most common cardiovascular diseases and one of the leading causes to death around the world (1). In 2012, the death toll of the cardiovascular disease reached 17.5 million, accounting for more than 31% of the global deaths. ASCVD is a chronic disease, which has two primary forms: one is ischaemic heart disease; another is a cerebrovascular disease (2). The occurrence of ASCVD has multiple intrinsic factors, which include the accumulation of immune cells (such as microphages), production of pro-inflammatory cytokines (CCL2, TNFa, IL-1B, and IL-6) and dysfunction of endothelial and vascular smooth muscle cells (3-5). The external risk factors of cardiovascular disease include hypertension, hyperlipidemia, high cholesterol, diabetes, obesity, smoking, and an unhealthy lifestyle. Cardiovascular complications are a major threat to patients with type II diabetes and new updated strategies for prevention are urgently demanded (6). Current available myriad studies have revealed that...
Atherosclerosis could occur in any arterial blood vessels, and lead to many related diseases, such as ischemic heart, peripheral artery and chronic kidney diseases etc. (7-12).

With the development of bioinformatics, text mining and data analysis have been used in many aspects, like the identification of potential key gene targets, signal pathway, diagnosis of diseases and prediction of the occurrence of diseases. Meanwhile, researchers have discovered a series of mechanisms of atherosclerosis by doing experiments (13). Compared with bioinformatics in the cancer field, there are fewer researches focused on cardiovascular diseases through text mining and data analysis.

In this study, we first used several bioinformatics strategies, such as text mining and microarray data analysis, to obtain the common genes, which their gene expressions have changed between advanced atherosclerosis plaque and early atherosclerosis plaque group, and the correlation between/within genes have existed in these genes. Then we clustered these genes in protein and protein interactions (PPI) and identified significant module genes that have more interactions. Lastly, drug-gene interaction of module genes was carried out in the drug gene interaction database (DGIdb), and aimed at finding some existed drugs to provide new ideas and basis for the prevention and treatment of cardiovascular disease. Figure 1 shows the framework of this study.

Methods

Text mining, microarray data analysis

Firstly, the open-access website pubmed2ensembl was used to perform text mining (http://pubmed2ensembl.ls.manchester.ac.uk). When a keyword is entered, the pubmed2ensembl website can retrieve and extract all gene symbols found in published PubMed articles related to keyword (14). We input the “Atherosclerosis” keyword into pubmed2ensembl and then extracted all unduplicated genes, these gene sets make up the text mining genes (TMGs).

Secondly, GSE28829 raw expression profiles (.CEL format files) and meta clinical information data (.soft format file) have been retrieved and downloaded from NCBI-GEO website (15,16), which was executed on the GPL570 platform. GSE28829 datasets contain 16 advanced atherosclerosis plaques (EA) and 13 early atherosclerosis plaques (AA) from carotid artery samples (17,18). We transformed probe identification numbers into official gene symbols via the information built in GPL570 platform, the non-mRNA probes were removed and the multiple probes to the same gene were dealt with to retain the significant value as the gene expression level. Then, we used affy, affyPLM, and limma packages loaded on R/Rstudio to detect the differentially expressed genes (DEGs) between EA and AA samples (19,20). DEGs with the |log2 fold change (FC)| ≥1 and adjust P value <0.05, corrected by the BH method, as the threshold criteria were selected for the follow-up analyses.

The intersection of TMGs and DEGs were overlapping genes, and then for the next further analysis.

Gene ontology (GO) and pathway enrichment analysis

The GO analysis is a ubiquitous and useful method for annotating gene products and its features of functional characteristics. GO is categorized into three groups (biological process, cellular component, molecular function). The Kyoto Encyclopedia of Genes and Genomes (KEGG) (21) is an open access informatic database from Japan for interpreting biological function and characteristics of the organic system, generated by the gene-chip and high-throughput experiments. The GO and KEGG enrichment of Overlapping genes were analyzed via an online tool DAVID, a functional annotation bioinformatics microarray analysis website, used to gene annotation, visualization. P<0.05 was considered as statistically significant as the threshold.

Protein interaction and module analysis

STRING database (version 11.0), covering about 24.6M proteins and more than 3.1 billion interactions originated from 5.09K organisms, was known as the primary source to depict and display the interaction among various proteins. Firstly, we uploaded overlapping genes into the STRING website, and a minimum interaction score >0.4 (low confidence) was set as significant threshold. Then the TSV format file of protein-protein interaction (PPI) was downloaded, and PPI networks were constructed by Cytoscape software. Subsequently, the Molecular Complex Detection (MCODE) and STRING app built in Cytoscape was utilized to classify the significant gene modules (clusters), which have highly interconnected clusters in the PPI network. The parameters in MCODE were set by default. The genes in gene modules were performed drug-gene interaction analysis.
**Figure 1** An overview of the workflow. Text mining for TMGs, Microarray data analysis for DEGs.

**Drug-gene interaction and functional analysis of potential genes**

The drug-gene interaction database (DGIdb: http://www.dgidb.org) is an open-source and supports searching, browsing and filtering of information on drug-gene interactions based on over thirty trusted sources. The module genes, as the potential targets, were pasted into the drug-gene database to search for existing drugs or compounds. These potential genes which have matched drugs were obtained and also performed functional enrichment analysis.

**Statistics analysis**

The moderate t-test was applied to identify DEGs, Fisher's Exact test was used to analyzed GO and KEGG enrichments (22). All statistical analysis was executed in R version 3.6.1 software.

**Results**

**TMGs & DEGs acquisition**

Based on the text mining and microarray data analysis strategy that is described in the methods section, 1,788 TMGs were related to atherosclerosis, 275 DEGs were identified in AA compared with EA group, and 93 genes were overlapping between TMGs and DEGs (Figure 1). Among these overlapping genes, 89 genes were up-regulated genes and 4 genes were down-regulated genes.
Table 1 The 93 common genes between TMGs and DEGs

<table>
<thead>
<tr>
<th>Common genes</th>
<th>Gene names</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up-regulated genes</td>
<td>CHI3L1, PTPRC, RGS1, NCF2, FCGR2A, SLC11A1, IFI16, HLA-MA, CTSS, VCAM1*, CXCR4*, CP, IL1RN, TNFAIP3, SGK1, CD86*, SOCS3, MARCKS, IL10RA, Tie1, C2, VAMP8, MMP12, C5AR1*, CTSC, PIK3CG, APOE, SCAR, UCP2, PLA2G7, CYBA, MAFB, PTGS1, LIPI, HP, TNC, PLA2G2A, CCR1*, CD36, CYP1B1, CPM, ABCA1, CX3CR1, ANP, EDN1, CD83, LY96, SPP1, CCL19, MMRN1, RAC2, IER3, RALA, CD14, SERPINA1, VEGF, AIF1, CCL8, CCL5, SLC2A5, CCL18, CCL4, ITGA1, ITGAX, BCL2A1, PLTP, TLR2, CSF1R*, MMP9, CD74, CD209, CXL2, F13A1, LYN, ITGB2*, TLR8*, CXCL16, PTGER4, C3AR1, CD163, ADAMDEC1, ADAM28, ALOX5AP, FCGR2B, TIAM1, MSR1, CTSB, EPB41L3</td>
</tr>
<tr>
<td>Down-regulated genes</td>
<td>RBP4, KCNMA1, MYOCD, CNN1, PPP1R1A</td>
</tr>
</tbody>
</table>

*, the final eight genes.

Figure 2 The top six significant GO terms and KEGG pathways of common genes. The bar charts represent the counts of genes classified in the BP, CC, MF and KEGG respectively; the yellow line chart represents the significance of enrichment terms. GO, gene ontology; BP, biological process; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes.

(Table 1).

**GO and pathway enrichment analysis**

In order to demonstrate GO and signal pathway enrichments of common genes, we executed functional annotation in DAVID website. As shown in Figure 2, it showed that the top six significant enrichment terms for BP, CC, MF, and KEGG signal pathways of common genes. In BP category, it was mainly enriched in the defense response, inflammatory response, and response to external stimulus. In CC category, it was significantly enriched...
in the extracellular space, extracellular region part, and extracellular part. In MF category, it was mainly enriched in the chemokine activity, cytokine binding, and receptor activity. As for signal pathway enrichment, it was mainly involved in the phagosome, chemokine signaling pathway, and staphylococcus aureus infection terms, respectively (Figure 2).

**Protein interaction and module analysis**

All of the common genes were pasted into the STRING website and then analyzed with Cytoscape software. A total of 88 genes/nodes with 705 edges were involved in the construction of the PPI networks, and 5 genes didn’t fall into the PPI networks (Figure 3A). To get the most significant gene modules, a significant gene module was
selected by using the MCODE application. Module 1 consists 23 genes/nodes with 232 edges/interactions, which all exhibit up-regulated (Figure 3B).

Drug-gene interaction and functional analysis of potential genes

The 23 genes clustered in the significant gene module were selected for drug-gene interaction analysis. We found that there were eight genes target to 20 potential existing drugs, which have been divided into 4 drug-gene interaction types and all have their initial drug indications (Figure 4A, Table 2). Besides, the functional enrichment terms of those eight gene were mainly involved in 11 GO terms (Figure 4B, Table 3), the most significant GO terms were the inflammatory response (BP, adj.pval =3.17E-04), cell surface (CC, adj. pval =1.36E-04), molecular transducer activity (MF, adj.pval =1.13E-02), respectively (Figure 4B, Table 3).

Availability of data and materials

The data associated with this article has been deposited in the NCBI-GEO website (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi).

Discussion

Atherosclerotic cardiovascular disease is considered to be a common and chronic inflammatory malady of the arterial intima. In this study, our purposes were to discover new drug indications. As we expected, we finally have found eight genes, namely VCAM1, CSF1R, C5AR1, CXCR4, CD86, CCR1, ITGB2, and TLR8, target to 20 existing potential drugs which might be used for the treatment of atherosclerosis-related diseases.

In our study, we have identified 20 drugs, which have target to eight genes (VCAM1, CSF1R, C5AR1, CXCR4, CD86, CCR1, ITGB2, and TLR8). These genes all have correlation with atherosclerosis. Almeda et al. team have discovered that the vascular cell adhesion molecule-1 (VCAM1) exposed to cytokines have shown potential for drug delivery (23). The inhibition of the progression of atherosclerosis has related to the interaction between miR-155 and B-cell leukemia/lymphoma, when miR-155 suppressed macrophage proliferation by targeting colony-stimulating factor-1 receptor (CSF1R) (24). High levels of C5a receptor 1 (C5AR1) in human lung tumors were significantly associated with overall survival and bone metastasis (25). Type 4 chemokine receptor (CXCR4) participated in immune cell migration during the progression of atherosclerosis (26) and its expression level has been treated as a promising target for molecular imaging in atherosclerosis (27). CD86 is expressed on the antigen-presenting cells (APCs) and provides costimulatory signals to T cells. Meletta et al. adopt CD86/CD80 as an imaging probe for atherosclerosis diagnosis (28). Han et al. have demonstrated that CC chemokine ligand 7 (CCL7) and its receptors CCR1, CCR2, and CCR3 were high expressions significantly in lung cancer bone metastasis (29). Moreover, CCR1 is also a target of the EGF-AKT-mTOR-STAT3 signaling pathway in breast cancer (30). The differentially methylated regions in integrin subunit beta 2 (ITGB2) may mediate genetic risk in inflammatory disease (31).

Toll-like receptor 8 (TLR8), a member of TLRs, has correlation with inflammatory disease (32). A large amount of recent evidence confirms that the occurrence and development of atherosclerotic cardiovascular disease is a chronic inflammatory process. Inflammation is one of the most important intrinsic factors that cause plaque vulnerability. Based on previous scientific research, Janus-activated kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway play an important role in inflammation, chronic pain, and even have an effect on the pathogenesis of neuropathic pain. Proinflammatory cytokines interleukin (IL-1β) is a downstream factor involved in JAK2/STAT3 signal transition pathway, which participates in neuron injury and inflammation (33). As the important signal pathway connecting inflammation and tumor, activated signal transduction and transcriptional activation factor 3 (STAT3) leads to genetic abnormal expression, gene silencing, genomic instability, etc. in non-small cell lung cancer (NSCLC) cells, and induces therapeutic resistance (34).

Currently, the interaction between the drugs and genes we discovered were divided into four types, namely agonist, inhibitor, antagonist, and binder (Table 3). These drugs are classified into anti-inflammatory agent, anti-neoplastic and immunomodulating agents. Although these existing drugs provide a new perspective for us to study cardiovascular diseases, further clinical trials need to be performed for confirmation of its new function and indications.

Conclusions

According to the text mining conception (keyword: atherosclerosis) and microarray data analysis (dataset: © Annals of Palliative Medicine. All rights reserved. Ann Palliat Med 2020 | http://dx.doi.org/10.21037/apm-20-705
Figure 4. The drugs targeted to genes and its functional enrichment analysis. (A) Chord plot for the connection between 20 drugs and 8 genes; (B) chord plot for functional enrichments of 8 genes.
Table 2 The specified information of drugs and its target genes

<table>
<thead>
<tr>
<th>Number</th>
<th>Gene</th>
<th>Drug</th>
<th>Interaction</th>
<th>Drug class*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>TLR8</td>
<td>Imiquimod</td>
<td>Agonist</td>
<td>Anti-wart agent, antineoplastic agent</td>
</tr>
<tr>
<td>2</td>
<td>TLR8</td>
<td>Ethynodiol diacetate</td>
<td>Agonist</td>
<td>Contraceptives, oral, synthetic</td>
</tr>
<tr>
<td>3</td>
<td>ITGB2</td>
<td>Simvastatin</td>
<td>Other</td>
<td>Antihypertensive agent</td>
</tr>
<tr>
<td>4</td>
<td>ITGB2</td>
<td>Lifitegrast</td>
<td>Antagonist</td>
<td>Anti-inflammatory agent</td>
</tr>
<tr>
<td>5</td>
<td>CCR1</td>
<td>Glycerin</td>
<td>Agonist</td>
<td>Cryoprotective agents</td>
</tr>
<tr>
<td>6</td>
<td>CCR1</td>
<td>Phenprocoumon</td>
<td>Antagonist</td>
<td>Hematologic agents, fibrinolytic agents</td>
</tr>
<tr>
<td>7</td>
<td>CD86</td>
<td>Abatacept</td>
<td>Inhibitor, binder, antagonist</td>
<td>Antineoplastic and immunomodulating agents, antirheumatic agents, immunosuppressive agents</td>
</tr>
<tr>
<td>8</td>
<td>CD86</td>
<td>Belatacept</td>
<td>Inhibitor</td>
<td>Immunosuppressive agents, antineoplastic and immunomodulating agents</td>
</tr>
<tr>
<td>9</td>
<td>CXCR4</td>
<td>Plerixafor</td>
<td>Antagonist, partial agonist</td>
<td>Antineoplastic agent, antineoplastic and immunomodulating agents, anti-retroviral agents, anti-infective agents, anti-HIV agents</td>
</tr>
<tr>
<td>10</td>
<td>CXCR4</td>
<td>Phenprocoumon</td>
<td>Antagonist</td>
<td>Hematologic agents, fibrinolytic agents</td>
</tr>
<tr>
<td>11</td>
<td>C5AR1</td>
<td>Amprenavir</td>
<td>Antagonist</td>
<td>Not available</td>
</tr>
<tr>
<td>12</td>
<td>C5AR1</td>
<td>Lopinavir</td>
<td>Antagonist</td>
<td>Not available</td>
</tr>
<tr>
<td>13</td>
<td>CSF1R</td>
<td>Pazopanib</td>
<td>Inhibitor</td>
<td>Antineoplastic agent, moderate risk QTC-prolonging agents, immunosuppressive agents, antineoplastic and immunomodulating agents</td>
</tr>
<tr>
<td>14</td>
<td>CSF1R</td>
<td>Sunitinib</td>
<td>Inhibitor</td>
<td>Antineoplastic agent, immunosuppressive agents, hypoglycemia-associated agents, blood glucose lowering agents, antineoplastic and immunomodulating agents, angiogenesis modulating agents</td>
</tr>
<tr>
<td>15</td>
<td>CSF1R</td>
<td>Pazopanib hydrochloride</td>
<td>Inhibitor</td>
<td>Not available</td>
</tr>
<tr>
<td>16</td>
<td>CSF1R</td>
<td>Sunitinib malate</td>
<td>Inhibitor</td>
<td>Not available</td>
</tr>
<tr>
<td>17</td>
<td>CSF1R</td>
<td>Dasatinib</td>
<td>Inhibitor</td>
<td>Not available</td>
</tr>
<tr>
<td>18</td>
<td>CSF1R</td>
<td>Pegfilgrastim</td>
<td>Binder</td>
<td>Anti-neutropenic agents, antineoplastic and immunomodulating agents, anti-neutropenic agents</td>
</tr>
<tr>
<td>19</td>
<td>CSF1R</td>
<td>Filgrastim</td>
<td>Binder</td>
<td>Anti-neutropenic agents</td>
</tr>
<tr>
<td>20</td>
<td>VCAM1</td>
<td>Carvedilol</td>
<td>Inhibitor</td>
<td>Vasodilator agents, neurotransmitter agents, hypotensive agents, cardiovascular agents, bradycardia-causing agents, beta blocking agents, antihypertensive agents, alpha and beta blocking agents, adrenergic agents, antihypertensive agents</td>
</tr>
</tbody>
</table>

*, the drug indications have been approved by FDA.
Table 3 The functional enrichments of the final 8 genes

<table>
<thead>
<tr>
<th>Category</th>
<th>ID</th>
<th>Term</th>
<th>Genes</th>
<th>adj_pval</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP</td>
<td>GO:0006954</td>
<td>Inflammatory response</td>
<td>VCAM1, C5AR1, CXCR4, CCR1, ITGB2, TLR8, CSF1R</td>
<td>3.17E-05</td>
</tr>
<tr>
<td>BP</td>
<td>GO:0006952</td>
<td>Defense response</td>
<td>VCAM1, CD86, C5AR1, CXCR4, CCR1, ITGB2, TLR8, CSF1R</td>
<td>7.91E-05</td>
</tr>
<tr>
<td>BP</td>
<td>GO:0009605</td>
<td>Response to external stimulus</td>
<td>VCAM1, CD86, C5AR1, CXCR4, CCR1, ITGB2, TLR8, CSF1R</td>
<td>7.03E-04</td>
</tr>
<tr>
<td>BP</td>
<td>GO:0006935</td>
<td>Chemotaxis</td>
<td>VCAM1, C5AR1, CXCR4, CCR1, ITGB2, CSF1R</td>
<td>0.00119549</td>
</tr>
<tr>
<td>BP</td>
<td>GO:0042330</td>
<td>Taxis</td>
<td>VCAM1, C5AR1, CXCR4, CCR1, ITGB2, CSF1R</td>
<td>0.00120627</td>
</tr>
<tr>
<td>BP</td>
<td>GO:0060326</td>
<td>Cell chemotaxis</td>
<td>VCAM1, C5AR1, CXCR4, CCR1, ITGB2</td>
<td>0.00260446</td>
</tr>
<tr>
<td>BP</td>
<td>GO:0051240</td>
<td>Positive regulation of multicellular organismal process</td>
<td>CD86, C5AR1, CXCR4, CCR1, ITGB2, TLR8, CSF1R</td>
<td>0.00395928</td>
</tr>
<tr>
<td>BP</td>
<td>GO:0006955</td>
<td>Immune response</td>
<td>VCAM1, CD86, C5AR1, CCR1, ITGB2, TLR8, CSF1R</td>
<td>0.00638104</td>
</tr>
<tr>
<td>BP</td>
<td>GO:0050900</td>
<td>Leukocyte migration</td>
<td>VCAM1, C5AR1, CXCR4, CCR1, ITGB2</td>
<td>0.01298062</td>
</tr>
<tr>
<td>BP</td>
<td>GO:002684</td>
<td>Positive regulation of immune system process</td>
<td>VCAM1, CD86, C5AR1, CCR1, ITGB2</td>
<td>0.0183702</td>
</tr>
<tr>
<td>BP</td>
<td>GO:0048584</td>
<td>Positive regulation of response to stimulus</td>
<td>CD86, C5AR1, CXCR4, CCR1, ITGB2, TLR8, CSF1R</td>
<td>0.03128537</td>
</tr>
<tr>
<td>CC</td>
<td>GO:009986</td>
<td>Cell surface</td>
<td>VCAM1, CD86, C5AR1, CXCR4, CCR1, ITGB2, CSF1R</td>
<td>1.36E-04</td>
</tr>
<tr>
<td>MF</td>
<td>GO:0060089</td>
<td>Molecular transducer activity</td>
<td>CD86, C5AR1, CXCR4, CCR1, ITGB2, TLR8, CSF1R</td>
<td>0.01136872</td>
</tr>
<tr>
<td>MF</td>
<td>GO:004872</td>
<td>Receptor activity</td>
<td>CD86, C5AR1, CXCR4, CCR1, ITGB2, TLR8, CSF1R</td>
<td>0.01136872</td>
</tr>
</tbody>
</table>

GSE28829), we found 20 existing drugs, approved by FDA, target to eight genes, which involved in the inflammatory pathway. These genes might be used for atherosclerosis, as well as its original drug indications.

Acknowledgments

Funding: This study was supported by the National Natural Science Foundation of China (No. 81770294).

Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/apm-20-705). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. For human datasets mentioned in this study, please refer to the original article (PMID: 22388324). We just re-analyzed the open accessed datasets, and no ethical approval was required by the local ethics committees.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


Cite this article as: Wan Z, Zhao B, Zhang X, Zhao Y. Drug discovery in cardiovascular disease identified by text mining and data analysis. Ann Palliat Med 2020. doi: 10.21037/apm-20-705